Announcements Trials
Browse Landscape

Phase

Phase 2 28Phase 1 4Phase 3 2Phase 1/2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Sarcoma 1CNS 1

Conditions

Gliosarcoma 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 125Radiotherapy 119Carboplatin 112Cisplatin 111pembrolizumab 110Nivolumab 106Docetaxel 90Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Bevacizumab 64Fluorouracil 63Etoposide 63Oxaliplatin 62Filgrastim 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58Capecitabine 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 53Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × enzastaurin × Clear all
NCT00452413 2021-05-13

A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer

Eli Lilly and Company

Phase 1/2 Completed
65 enrolled 18 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00402116 2020-08-06

Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients

Eli Lilly and Company

Phase 1/2 Completed
72 enrolled 19 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡